BSECompany Update7 Oct 2026 · 7 Oct 2026, 02:35 pm
In continuation of the Company''s letters dated 05/Sep/2026 and 15/Sep/2026, this is to inform you that the proposal to acquire 9.50% equity shares of common stock of Med Therapy Biotechnology Inc., USA stands terminated. The proposal to acquire 1.50% each of the equity shares of common stock of Med Therapy by Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters of the Company also stands terminated.
Sudarshan Pharma Industries Ltd · 543828
✦ AI SummaryOrder Cancel
Sudarshan Pharma Industries Ltd has terminated its proposal to acquire 9.50% equity shares of Med Therapy Biotechnology Inc. and also terminated the proposal to acquire 1.50% each of the equity shares by its promoters, Mr. Hemal Mehta and Mr. Sachin Mehta.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sudarshan Pharma Industries Ltd - 543828 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Attachments (1)
📄pdf
Download →
c46a44c9-fffa-49f9-9742-b8dcc63296ab.pdf
View document text
SUDARTHAX PHARIIA IIIDUOTRIES TTD
Head Office : 301 . Au ra Biplex Premum Beta I Premises, 7, S.V Boad, Borival (West), ft,lumba 400092
E-mail : compl ance@)sudarshanpharma.com Websile : www.sltdarshanpharma com
BoardLine : +91'22-42221111 i 13331111 i 42221116 (100 ljne) . CIN : 151 496[,1H2008P LC 1 84997
Date:7t'October 2026
sPL/CSISE/2026 27 /61
Th€ Listing Department
BSE Limited BSE Scrip Code:543828
Phlroze leeieebhoY Towers, BSE Trading Symbol: SUDARSHAN
Dalal Street, Murnbai 400 001 lS N: NEOOTVO1023
Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obli8ations and Disclosure
Requirements) Regulations, 2015
Ref: Updates on acquisition of M/s. MedTherapy giotechnology lnc, UsA-Company Letter bearing
daftd
ref. no. spfL/cs/sE/2026-2027l57 dated 5th september, 2026 and sPlLlcslsEl2o26'2o2715a
15th september,2026
Pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations' 2015
and n contlnUat]on of the Company,s lette15 bearing ref' no, s P lL/cs/s E/2 026.2021 157 daled
5 ' september, 2026 an d sPll/cslsE/2o26'2a27/58 clated 1sth september, 2026, this ls to inform vou
that the proposal to acqulre 9 50% equitY share! of common stock of Med Therapy Biotechnology lnc '
USA {"Med Therapy") stands terminated
The proposa to acqlire 150% each of the equity shares of common stock of Med TherapY' bY
N4r.HemalMehta(Chalrman&ManagngDirector)andMr'sachinMehta(JointManaglngDirector)'
Promoters of the Company also stands termlnated.
You are requested to take the same on record
For, Sudarshan Pharma lndustries Limited
lndll
HemalMehta
Chalrman & Managlng Director
Begd. Otl. : 301, Aura Biplex, Above Kalyan Jewellers, S.V Road, Borivali (West), lvumbai - 400092